{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:27:39Z","timestamp":1792801659718,"version":"4.5.0"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T00:00:00Z","timestamp":1701648000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T00:00:00Z","timestamp":1701648000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R01 AG059799"],"award-info":[{"award-number":["R01 AG059799"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["P30 MH075673"],"award-info":[{"award-number":["P30 MH075673"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000957","name":"Alzheimer's Association","doi-asserted-by":"publisher","award":["T-PEP-18-579974C"],"award-info":[{"award-number":["T-PEP-18-579974C"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Richman Family Precision Medicine Center of Excellence in Alzheimer's Disease","id":[{"id":"https:\/\/ror.org\/02y9qjz38","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["R25GM109441"],"award-info":[{"award-number":["R25GM109441"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Neurodegener"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cognitive decline in Alzheimer\u2019s disease (AD) is associated with hyperphosphorylated tau (pTau) propagation between neurons along synaptically connected networks, in part via extracellular vesicles (EVs). EV biogenesis is triggered by ceramide enrichment at the plasma membrane from neutral sphingomyelinase2 (nSMase2)-mediated cleavage of sphingomyelin. We report, for the first time, that human tau expression elevates brain ceramides and nSMase2 activity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>To determine the therapeutic benefit of inhibiting this elevation, we evaluated PDDC, the first potent, selective, orally bioavailable, and brain-penetrable nSMase2 inhibitor in the transgenic PS19 AD mouse model. Additionally, we directly evaluated the effect of PDDC on tau propagation in a mouse model where an adeno-associated virus (AAV) encoding P301L\/S320F double mutant human tau was stereotaxically-injected unilaterally into the hippocampus. The contralateral transfer of the double mutant human tau to the dentate gyrus was monitored. We examined ceramide levels, histopathological changes, and pTau content within EVs isolated from the mouse plasma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Similar to human AD, the PS19 mice exhibited increased brain ceramide levels and nSMase2 activity; both were completely normalized by PDDC treatment. The PS19 mice also exhibited elevated tau immunostaining, thinning of hippocampal neuronal cell layers, increased mossy fiber synaptophysin immunostaining, and glial activation, all of which were pathologic features of human AD. PDDC treatment reduced these changes. The plasma of PDDC-treated PS19 mice had reduced levels of neuronal- and microglial-derived EVs, the former carrying lower pTau levels, compared to untreated mice. In the tau propagation model, PDDC normalized the tau-induced increase in brain ceramides and significantly reduced the amount of tau propagation to the contralateral side.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>PDDC is a first-in-class therapeutic candidate that normalizes elevated brain ceramides and nSMase2 activity, leading to the slowing of tau spread in AD mice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40035-023-00383-9","type":"journal-article","created":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T05:02:57Z","timestamp":1701666177000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Inhibiting tau-induced elevated nSMase2 activity and ceramides is therapeutic in an Alzheimer\u2019s disease mouse model"],"prefix":"10.1186","volume":"12","author":[{"given":"Carolyn","family":"Tallon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin J.","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Medhinee M.","family":"Malvankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pragney","family":"Deme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Nogueras-Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erden","family":"Eren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajit G.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen R.","family":"Hollinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arindom","family":"Pal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Mustapic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meixiang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaleem","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tawnjerae R.","family":"Joe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana","family":"Rais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norman J.","family":"Haughey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2181-3118","authenticated-orcid":false,"given":"Dimitrios","family":"Kapogiannis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9814-4157","authenticated-orcid":false,"given":"Barbara S.","family":"Slusher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,4]]},"reference":[{"issue":"7","key":"383_CR1","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s40265-023-01858-9","volume":"83","author":"J Cummings","year":"2023","unstructured":"Cummings J. Anti-amyloid monoclonal antibodies are transformative treatments that redefine Alzheimer\u2019s disease therapeutics. Drugs. 2023;83(7):569\u201376.","journal-title":"Drugs"},{"key":"383_CR2","doi-asserted-by":"publisher","first-page":"101339","DOI":"10.1016\/j.arr.2021.101339","volume":"68","author":"KI Avgerinos","year":"2021","unstructured":"Avgerinos KI, Ferrucci L, Kapogiannis D. Effects of monoclonal antibodies against amyloid-beta on clinical and biomarker outcomes and adverse event risks: a systematic review and meta-analysis of phase III RCTs in Alzheimer\u2019s disease. Ageing Res Rev. 2021;68:101339.","journal-title":"Ageing Res Rev"},{"issue":"4","key":"383_CR3","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/BF00308809","volume":"82","author":"H Braak","year":"1991","unstructured":"Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239\u201359.","journal-title":"Acta Neuropathol"},{"issue":"11","key":"383_CR4","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1038\/s41591-022-02049-x","volume":"28","author":"R Ossenkoppele","year":"2022","unstructured":"Ossenkoppele R, Pichet Binette A, Groot C, Smith R, Strandberg O, Palmqvist S, et al. Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline. Nat Med. 2022;28(11):2381\u20137.","journal-title":"Nat Med"},{"issue":"1","key":"383_CR5","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.febslet.2011.11.022","volume":"586","author":"D Simon","year":"2012","unstructured":"Simon D, Garcia-Garcia E, Royo F, Falcon-Perez JM, Avila J. Proteostasis of tau. Tau overexpression results in its secretion via membrane vesicles. FEBS Lett. 2012;586(1):47\u201354.","journal-title":"FEBS Lett"},{"issue":"1","key":"383_CR6","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1001\/jamaneurol.2018.2505","volume":"76","author":"GS Gibbons","year":"2019","unstructured":"Gibbons GS, Lee VMY, Trojanowski JQ. Mechanisms of cell-to-cell transmission of pathological tau: a review. JAMA Neurol. 2019;76(1):101\u20138.","journal-title":"JAMA Neurol"},{"issue":"3","key":"383_CR7","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/acn3.176","volume":"2","author":"K Yanamandra","year":"2015","unstructured":"Yanamandra K, Jiang H, Mahan TE, Maloney SE, Wozniak DF, Diamond MI, et al. Anti-tau antibody reduces insoluble tau and decreases brain atrophy. Ann Clin Transl Neurol. 2015;2(3):278\u201388.","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"383_CR8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/d41573-020-00217-7","volume":"20","author":"A Mullard","year":"2021","unstructured":"Mullard A. Failure of first anti-tau antibody in Alzheimer disease highlights risks of history repeating. Nat Rev Drug Discov. 2021;20(1):3\u20135.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"383_CR9","doi-asserted-by":"publisher","first-page":"117","DOI":"10.4103\/1673-5374.340409","volume":"18","author":"BP Imbimbo","year":"2023","unstructured":"Imbimbo BP, Balducci C, Ippati S, Watling M. Initial failures of anti-tau antibodies in Alzheimer\u2019s disease are reminiscent of the amyloid-beta story. Neural Regen Res. 2023;18(1):117\u20138.","journal-title":"Neural Regen Res"},{"issue":"6","key":"383_CR10","doi-asserted-by":"publisher","first-page":"3842","DOI":"10.1074\/jbc.M111.277061","volume":"287","author":"S Saman","year":"2012","unstructured":"Saman S, Kim W, Raya M, Visnick Y, Miro S, Saman S, et al. Exosome-associated tau is secreted in tauopathy models and is selectively phosphorylated in cerebrospinal fluid in early Alzheimer disease. J Biol Chem. 2012;287(6):3842\u20139.","journal-title":"J Biol Chem"},{"issue":"1","key":"383_CR11","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1093\/brain\/awaa376","volume":"144","author":"Z Ruan","year":"2021","unstructured":"Ruan Z, Pathak D, Venkatesan Kalavai S, Yoshii-Kitahara A, Muraoka S, Bhatt N, et al. Alzheimer\u2019s disease brain-derived extracellular vesicles spread tau pathology in interneurons. Brain. 2021;144(1):288\u2013309.","journal-title":"Brain"},{"issue":"5867","key":"383_CR12","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1126\/science.1153124","volume":"319","author":"K Trajkovic","year":"2008","unstructured":"Trajkovic K, Hsu C, Chiantia S, Rajendran L, Wenzel D, Wieland F, et al. Ceramide triggers budding of exosome vesicles into multivesicular endosomes. Science. 2008;319(5867):1244\u20137.","journal-title":"Science"},{"key":"383_CR13","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1016\/j.drudis.2021.03.025","volume":"26","author":"C Tallon","year":"2021","unstructured":"Tallon C, Hollinger KR, Pal A, Bell BJ, Rais R, Tsukamoto T, et al. Nipping disease in the bud: nSMase2 inhibitors as therapeutics in extracellular vesicle-mediated diseases. Drug Discovery Today. 2021;26:1656\u201368.","journal-title":"Drug Discovery Today"},{"issue":"13","key":"383_CR14","doi-asserted-by":"publisher","first-page":"2940","DOI":"10.1002\/jnr.22438","volume":"88","author":"N Tabatadze","year":"2010","unstructured":"Tabatadze N, Savonenko A, Song H, Bandaru VV, Chu M, Haughey NJ. Inhibition of neutral sphingomyelinase-2 perturbs brain sphingolipid balance and spatial memory in mice. J Neurosci Res. 2010;88(13):2940\u201351.","journal-title":"J Neurosci Res"},{"issue":"10","key":"383_CR15","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.3390\/pharmaceutics14102066","volume":"14","author":"C Tallon","year":"2022","unstructured":"Tallon C, Bell BJ, Sharma A, Pal A, Malvankar MM, Thomas AG, et al. Dendrimer-conjugated nSMase2 inhibitor reduces tau propagation in mice. Pharmaceutics. 2022;14(10):2066.","journal-title":"Pharmaceutics"},{"issue":"11","key":"383_CR16","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1038\/nn.4132","volume":"18","author":"H Asai","year":"2015","unstructured":"Asai H, Ikezu S, Tsunoda S, Medalla M, Luebke J, Haydar T, et al. Depletion of microglia and inhibition of exosome synthesis halt tau propagation. Nat Neurosci. 2015;18(11):1584\u201393.","journal-title":"Nat Neurosci"},{"key":"383_CR17","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1021\/acschembio.0c00311","volume":"15","author":"T Bilousova","year":"2020","unstructured":"Bilousova T, Simmons BJ, Knapp RR, Elias CJ, Campagna J, Melnik M, et al. Dual neutral sphingomyelinase-2\/acetylcholinesterase inhibitors for the treatment of Alzheimer\u2019s disease. ACS Chem Biol. 2020;15:1671\u201384.","journal-title":"ACS Chem Biol"},{"issue":"19","key":"383_CR18","doi-asserted-by":"publisher","first-page":"3857","DOI":"10.1111\/bph.14789","volume":"176","author":"C Rojas","year":"2019","unstructured":"Rojas C, Sala M, Thomas AG, Datta Chaudhuri A, Yoo SW, Li Z, et al. A novel and potent brain penetrant inhibitor of extracellular vesicle release. Br J Pharmacol. 2019;176(19):3857\u201370.","journal-title":"Br J Pharmacol"},{"issue":"11","key":"383_CR19","doi-asserted-by":"publisher","first-page":"6028","DOI":"10.1021\/acs.jmedchem.0c00278","volume":"63","author":"M Sala","year":"2020","unstructured":"Sala M, Hollinger KR, Thomas AG, Dash RP, Tallon C, Veeravalli V, et al. Novel human neutral sphingomyelinase 2 inhibitors as potential therapeutics for Alzheimer disease. J Med Chem. 2020;63(11):6028\u201356.","journal-title":"J Med Chem"},{"key":"383_CR20","doi-asserted-by":"publisher","first-page":"114796","DOI":"10.1016\/j.bcp.2021.114796","volume":"194","author":"C Tallon","year":"2021","unstructured":"Tallon C, Picciolini S, Yoo S-W, Thomas AG, Pal A, Alt J, et al. Inhibition of neutral sphingomyelinase 2 reduces extracellular vesicle release from neurons, oligodendrocytes, and activated microglial cells following acute brain injury. Biochem Pharmacol. 2021;194:114796.","journal-title":"Biochem Pharmacol."},{"issue":"3","key":"383_CR21","doi-asserted-by":"publisher","first-page":"537","DOI":"10.3233\/JAD-2011-111202","volume":"29","author":"V Filippov","year":"2012","unstructured":"Filippov V, Song MA, Zhang K, Vinters HV, Tung S, Kirsch WM, et al. Increased ceramide in brains with Alzheimer\u2019s and other neurodegenerative diseases. J Alzheimers Dis. 2012;29(3):537\u201347.","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"383_CR22","doi-asserted-by":"publisher","first-page":"231","DOI":"10.3233\/JAD-200964","volume":"81","author":"UD Teitsdottir","year":"2021","unstructured":"Teitsdottir UD, Halldorsson S, Rolfsson O, Lund SH, Jonsdottir MK, Snaedal J, et al. Cerebrospinal fluid C18 ceramide associates with markers of Alzheimer\u2019s disease and inflammation at the pre- and early stages of dementia. J Alzheimers Dis. 2021;81(1):231\u201344.","journal-title":"J Alzheimers Dis"},{"issue":"5","key":"383_CR23","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.jalz.2010.03.014","volume":"6","author":"MM Mielke","year":"2010","unstructured":"Mielke MM, Haughey NJ, Ratnam Bandaru VV, Schech S, Carrick R, Carlson MC, et al. Plasma ceramides are altered in mild cognitive impairment and predict cognitive decline and hippocampal volume loss. Alzheimers Dement. 2010;6(5):378\u201385.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"383_CR24","doi-asserted-by":"publisher","first-page":"819","DOI":"10.3233\/JAD-160925","volume":"60","author":"MM Mielke","year":"2017","unstructured":"Mielke MM, Haughey NJ, Han D, An Y, Bandaru VVR, Lyketsos CG, et al. The association between plasma ceramides and sphingomyelins and risk of Alzheimer\u2019s disease differs by sex and APOE in the Baltimore longitudinal study of aging. J Alzheimers Dis. 2017;60(3):819\u201328.","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"383_CR25","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.neuroscience.2004.08.056","volume":"130","author":"H Satoi","year":"2005","unstructured":"Satoi H, Tomimoto H, Ohtani R, Kitano T, Kondo T, Watanabe M, et al. Astroglial expression of ceramide in Alzheimer\u2019s disease brains: a role during neuronal apoptosis. Neuroscience. 2005;130(3):657\u201366.","journal-title":"Neuroscience"},{"issue":"4","key":"383_CR26","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1002\/ana.10312","volume":"52","author":"RG Cutler","year":"2002","unstructured":"Cutler RG, Pedersen WA, Camandola S, Rothstein JD, Mattson MP. Evidence that accumulation of ceramides and cholesterol esters mediates oxidative stress-induced death of motor neurons in amyotrophic lateral sclerosis. Ann Neurol. 2002;52(4):448\u201357.","journal-title":"Ann Neurol"},{"issue":"4","key":"383_CR27","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1002\/ana.410300410","volume":"30","author":"RD Terry","year":"1991","unstructured":"Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R, et al. Physical basis of cognitive alterations in alzheimer\u2019s disease: Synapse loss is the major correlate of cognitive impairment. Ann Neuro. 1991;30(4):572\u201380.","journal-title":"Ann Neuro"},{"issue":"8925","key":"383_CR28","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/S0140-6736(94)92338-8","volume":"344","author":"MJ West","year":"1994","unstructured":"West MJ, Coleman PD, Flood DG, Troncoso JC. Differences in the pattern of hippocampal neuronal loss in normal ageing and Alzheimer\u2019s disease. Lancet. 1994;344(8925):769\u201372.","journal-title":"Lancet"},{"issue":"3","key":"383_CR29","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1161\/STROKEAHA.111.636498","volume":"43","author":"E Gemmell","year":"2012","unstructured":"Gemmell E, Bosomworth H, Allan L, Hall R, Khundakar A, Oakley AE, et al. Hippocampal neuronal atrophy and cognitive function in delayed poststroke and aging-related dementias. Stroke. 2012;43(3):808\u201314.","journal-title":"Stroke"},{"issue":"12","key":"383_CR30","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1021\/acsmedchemlett.2c00404","volume":"13","author":"R-D Gao","year":"2022","unstructured":"Gao R-D, Maeda M, Tallon C, Feinberg AP, Slusher BS, Tsukamoto T. Effects of 6-aminonicotinic acid esters on the reprogrammed epigenetic state of distant metastatic pancreatic carcinoma. ACS Med Chem Lett. 2022;13(12):1892\u20137.","journal-title":"ACS Med Chem Lett"},{"issue":"1","key":"383_CR31","doi-asserted-by":"publisher","first-page":"e991","DOI":"10.1038\/tp.2016.254","volume":"7","author":"SW Yoo","year":"2017","unstructured":"Yoo SW, Bae M, Tovar-Y-Romo LB, Haughey NJ. Hippocampal encoding of interoceptive context during fear conditioning. Transl Psychiatry. 2017;7(1):e991.","journal-title":"Transl Psychiatry"},{"issue":"5","key":"383_CR32","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1111\/j.1471-4159.2009.06038.x","volume":"109","author":"D Wheeler","year":"2009","unstructured":"Wheeler D, Knapp E, Bandaru VV, Wang Y, Knorr D, Poirier C, et al. Tumor necrosis factor-alpha-induced neutral sphingomyelinase-2 modulates synaptic plasticity by controlling the membrane insertion of NMDA receptors. J Neurochem. 2009;109(5):1237\u201349.","journal-title":"J Neurochem"},{"issue":"19","key":"383_CR33","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.1093\/hmg\/ddz151","volume":"28","author":"EJ Koller","year":"2019","unstructured":"Koller EJ, de la Cruz EG, Machula T, Ibanez KR, Lin W-L, Williams T, et al. Combining P301L and S320F tau variants produces a novel accelerated model of tauopathy. Hum Mol Genet. 2019;28(19):3255\u201369.","journal-title":"Hum Mol Genet"},{"issue":"3","key":"383_CR34","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.neuron.2007.01.010","volume":"53","author":"Y Yoshiyama","year":"2007","unstructured":"Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido TC, et al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron. 2007;53(3):337\u201351.","journal-title":"Neuron"},{"issue":"5","key":"383_CR35","doi-asserted-by":"publisher","first-page":"e0124481","DOI":"10.1371\/journal.pone.0124481","volume":"10","author":"M Figuera-Losada","year":"2015","unstructured":"Figuera-Losada M, Stathis M, Dorskind JM, Thomas AG, Bandaru VV, Yoo SW, et al. Cambinol, a novel inhibitor of neutral sphingomyelinase 2 shows neuroprotective properties. PLOS ONE. 2015;10(5):e0124481.","journal-title":"PLOS ONE"},{"issue":"8","key":"383_CR36","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1139\/o59-099","volume":"37","author":"EG Bligh","year":"1959","unstructured":"Bligh EG, Dyer WJ. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959;37(8):911\u20137.","journal-title":"Can J Biochem Physiol"},{"key":"383_CR37","doi-asserted-by":"publisher","first-page":"105734","DOI":"10.1016\/j.nbd.2022.105734","volume":"169","author":"X Zhu","year":"2022","unstructured":"Zhu X, Hollinger KR, Huang Y, Borjabad A, Kim BH, Arab T, et al. Neutral sphingomyelinase 2 inhibition attenuates extracellular vesicle release and improves neurobehavioral deficits in murine HIV. Neurobiol Dis. 2022;169:105734.","journal-title":"Neurobiol Dis"},{"issue":"2","key":"383_CR38","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/ana.10828","volume":"55","author":"NJ Haughey","year":"2004","unstructured":"Haughey NJ, Cutler RG, Tamara A, McArthur JC, Vargas DL, Pardo CA, et al. Perturbation of sphingolipid metabolism and ceramide production in HIV-dementia. Ann Neurol. 2004;55(2):257\u201367.","journal-title":"Ann Neurol"},{"issue":"18","key":"383_CR39","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1212\/01.wnl.0000260610.79853.47","volume":"68","author":"VV Bandaru","year":"2007","unstructured":"Bandaru VV, McArthur JC, Sacktor N, Cutler RG, Knapp EL, Mattson MP, et al. Associative and predictive biomarkers of dementia in HIV-1-infected patients. Neurology. 2007;68(18):1481\u20137.","journal-title":"Neurology"},{"key":"383_CR40","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/978-1-4939-7816-8_26","volume-title":"Amyloid Proteins: Methods and Protocols","author":"N Sahara","year":"2018","unstructured":"Sahara N, Kimura T. Biochemical properties of pathology-related tau species in tauopathy brains: an extraction protocol for tau oligomers and aggregates. In: Sigurdsson EM, Calero M, Gasset M, editors. Amyloid Proteins: Methods and Protocols. New York: Springer; 2018. p. 435\u201345."},{"issue":"2","key":"383_CR41","doi-asserted-by":"publisher","first-page":"126","DOI":"10.7150\/ntno.63158","volume":"6","author":"KR Hollinger","year":"2022","unstructured":"Hollinger KR, Sharma A, Tallon C, Lovell L, Thomas AG, Zhu X, et al. Dendrimer-2PMPA selectively blocks upregulated microglial GCPII activity and improves cognition in a mouse model of multiple sclerosis. Nanotheranostics. 2022;6(2):126\u201342.","journal-title":"Nanotheranostics"},{"issue":"9","key":"383_CR42","doi-asserted-by":"publisher","first-page":"4954","DOI":"10.1172\/JCI138179","volume":"130","author":"M Gratuze","year":"2020","unstructured":"Gratuze M, Leyns CEG, Sauerbeck AD, St-Pierre M-K, Xiong M, Kim N, et al. Impact of TREM2R47H variant on tau pathology\u2013induced gliosis and neurodegeneration. J Clin Invest. 2020;130(9):4954\u201368.","journal-title":"J Clin Invest"},{"issue":"5","key":"383_CR43","doi-asserted-by":"publisher","first-page":"993","DOI":"10.3390\/cells10050993","volume":"10","author":"F Delgado-Peraza","year":"2021","unstructured":"Delgado-Peraza F, Nogueras-Ortiz CJ, Volpert O, Liu D, Goetzl EJ, Mattson MP, et al. Neuronal and astrocytic extracellular vesicle biomarkers in blood reflect brain pathology in mouse models of Alzheimer\u2019s disease. Cells. 2021;10(5):993.","journal-title":"Cells"},{"issue":"1","key":"383_CR44","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12964-023-01045-z","volume":"21","author":"PA Gomes","year":"2023","unstructured":"Gomes PA, Bodo C, Nogueras-Ortiz C, Samiotaki M, Chen M, Soares-Cunha C, et al. A novel isolation method for spontaneously released extracellular vesicles from brain tissue and its implications for stress-driven brain pathology. Cell Commun Signal. 2023;21(1):35.","journal-title":"Cell Commun Signal"},{"key":"383_CR45","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.neurobiolaging.2021.09.006","volume":"109","author":"H Patel","year":"2022","unstructured":"Patel H, Martinez P, Perkins A, Taylor X, Jury N, McKinzie D, et al. Pathological tau and reactive astrogliosis are associated with distinct functional deficits in a mouse model of tauopathy. Neurobiol Aging. 2022;109:52\u201363.","journal-title":"Neurobiol Aging"},{"issue":"7","key":"383_CR46","doi-asserted-by":"publisher","first-page":"R82","DOI":"10.1186\/gb-2013-14-7-r82","volume":"14","author":"MM Simon","year":"2013","unstructured":"Simon MM, Greenaway S, White JK, Fuchs H, Gailus-Durner V, Wells S, et al. A comparative phenotypic and genomic analysis of C57BL\/6J and C57BL\/6N mouse strains. Genom Biol. 2013;14(7):R82.","journal-title":"Genom Biol"},{"issue":"4","key":"383_CR47","first-page":"375","volume":"55","author":"GP Otto","year":"2016","unstructured":"Otto GP, Rathkolb B, Oestereicher MA, Lengger CJ, Moerth C, Micklich K, et al. Clinical chemistry reference intervals for C57BL\/6J, C57BL\/6N, and C3HeB\/FeJ mice (Mus musculus). J Am Assoc Lab Anim Sci. 2016;55(4):375\u201386.","journal-title":"J Am Assoc Lab Anim Sci"},{"key":"383_CR48","unstructured":"Laboratory TJ. Physiological data summary\u2014C57BL\/6J (000664). Available from: https:\/\/jackson.jax.org\/rs\/444-BUH-304\/images\/physiological_data_000664.pdf"},{"key":"383_CR49","unstructured":"Charles River Larboratories International I. C57BL\/6 Mice Datasheet 2019. Available from: https:\/\/www.criver.com\/sites\/default\/files\/resources\/C57BL6MouseModelInformationSheet.pdf"},{"key":"383_CR50","unstructured":"Taconic Biosciences I. Automated Clinical Chemistry Analysis (ACCA) 2011 [updated 12\/19\/2011. 12\/19\/2011. Available from: https:\/\/www.taconic.com\/phenotypic-data\/automated-clinical-chemistry-analysis\/"},{"issue":"6","key":"383_CR51","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1016\/j.jalz.2014.06.008","volume":"11","author":"MS Fiandaca","year":"2015","unstructured":"Fiandaca MS, Kapogiannis D, Mapstone M, Boxer A, Eitan E, Schwartz JB, et al. Identification of preclinical Alzheimer\u2019s disease by a profile of pathogenic proteins in neurally derived blood exosomes: a case-control study. Alzheimers Dement. 2015;11(6):600\u20137.","journal-title":"Alzheimers Dement"},{"issue":"11","key":"383_CR52","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1001\/jamaneurol.2019.2462","volume":"76","author":"D Kapogiannis","year":"2019","unstructured":"Kapogiannis D, Mustapic M, Shardell MD, Berkowitz ST, Diehl TC, Spangler RD, et al. Association of extracellular vesicle biomarkers with Alzheimer disease in the Baltimore Longitudinal Study of Aging. JAMA Neurol. 2019;76(11):1340\u201351.","journal-title":"JAMA Neurol"},{"issue":"21","key":"383_CR53","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1021\/acschemneuro.0c00531","volume":"11","author":"BJ Bell","year":"2020","unstructured":"Bell BJ, Malvankar MM, Tallon C, Slusher BS. Sowing the seeds of discovery: tau-propagation models of Alzheimer\u2019s disease. ACS Chem Neurosci. 2020;11(21):3499\u2013509.","journal-title":"ACS Chem Neurosci"},{"issue":"11","key":"383_CR54","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1001\/jamaneurol.2019.2462","volume":"76","author":"D Kapogiannis","year":"2019","unstructured":"Kapogiannis D, Mustapic M, Shardell MD, Berkowitz ST, Diehl TC, Spangler RD, et al. Association of extracellular vesicle biomarkers with Alzheimer disease in the Baltimore Longitudinal Study of Aging. JAMA Neurol. 2019;76(11):1340\u201351.","journal-title":"JAMA Neurol"},{"issue":"9","key":"383_CR55","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1002\/alz.12130","volume":"16","author":"E Eren","year":"2020","unstructured":"Eren E, Hunt JFV, Shardell M, Chawla S, Tran J, Gu J, et al. Extracellular vesicle biomarkers of Alzheimer\u2019s disease associated with sub-clinical cognitive decline in late middle age. Alzheimers Dement. 2020;16(9):1293\u2013304.","journal-title":"Alzheimers Dement"},{"issue":"5867","key":"383_CR56","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1126\/science.1153124","volume":"319","author":"K Trajkovic","year":"2008","unstructured":"Trajkovic K, Hsu C, Chiantia S, Rajendran L, Wenzel D, Wieland F, et al. Ceramide triggers budding of exosome vesicles into multivesicular endosomes. Science. 2008;319(5867):1244\u20137.","journal-title":"Science"},{"issue":"8","key":"383_CR57","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.3390\/biomedicines10081956","volume":"10","author":"MR Chowdhury","year":"2022","unstructured":"Chowdhury MR, Jin HK, Bae JS. Diverse roles of ceramide in the progression and pathogenesis of Alzheimer\u2019s disease. Biomedicines. 2022;10(8):1956.","journal-title":"Biomedicines"},{"issue":"7","key":"383_CR58","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1073\/pnas.0305799101","volume":"101","author":"RG Cutler","year":"2004","unstructured":"Cutler RG, Kelly J, Storie K, Pedersen WA, Tammara A, Hatanpaa K, et al. Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer\u2019s disease. Proc Natl Acad Sci U S A. 2004;101(7):2070\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"383_CR59","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12974-019-1436-1","volume":"16","author":"NM de Wit","year":"2019","unstructured":"de Wit NM, den Hoedt S, Martinez-Martinez P, Rozemuller AJ, Mulder MT, de Vries HE. Astrocytic ceramide as possible indicator of neuroinflammation. J Neuroinflammation. 2019;16(1):48.","journal-title":"J Neuroinflammation"},{"issue":"1","key":"383_CR60","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1093\/brain\/awx320","volume":"141","author":"VJ Lowe","year":"2018","unstructured":"Lowe VJ, Wiste HJ, Senjem ML, Weigand SD, Therneau TM, Boeve BF, et al. Widespread brain tau and its association with ageing, Braak stage and Alzheimer\u2019s dementia. Brain. 2018;141(1):271\u201387.","journal-title":"Brain"},{"issue":"Pt 5","key":"383_CR61","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1093\/brain\/aww027","volume":"139","author":"R Ossenkoppele","year":"2016","unstructured":"Ossenkoppele R, Schonhaut DR, Scholl M, Lockhart SN, Ayakta N, Baker SL, et al. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer\u2019s disease. Brain. 2016;139(Pt 5):1551\u201367.","journal-title":"Brain"},{"issue":"44","key":"383_CR62","doi-asserted-by":"publisher","first-page":"eabh1448","DOI":"10.1126\/sciadv.abh1448","volume":"7","author":"G Meisl","year":"2021","unstructured":"Meisl G, Hidari E, Allinson K, Rittman T, DeVos SL, Sanchez JS, et al. In vivo rate-determining steps of tau seed accumulation in Alzheimer\u2019s disease. Sci Adv. 2021;7(44):eabh1448.","journal-title":"Sci Adv"},{"issue":"1","key":"383_CR63","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13195-022-01010-x","volume":"14","author":"TR Li","year":"2022","unstructured":"Li TR, Yao YX, Jiang XY, Dong QY, Yu XF, Wang T, et al. \u03b2-Amyloid in blood neuronal-derived extracellular vesicles is elevated in cognitively normal adults at risk of Alzheimer\u2019s disease and predicts cerebral amyloidosis. Alzheimers Res Ther. 2022;14(1):66.","journal-title":"Alzheimers Res Ther"},{"key":"383_CR64","doi-asserted-by":"publisher","first-page":"16019","DOI":"10.1038\/npjamd.2016.19","volume":"2","author":"E Eitan","year":"2016","unstructured":"Eitan E, Hutchison ER, Marosi K, Comotto J, Mustapic M, Nigam SM, et al. Extracellular vesicle-associated abeta mediates trans-neuronal bioenergetic and Ca(2+)-handling deficits in Alzheimer\u2019s disease models. NPJ Aging Mech Dis. 2016;2:16019.","journal-title":"NPJ Aging Mech Dis"},{"issue":"1","key":"383_CR65","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/s41467-017-00579-4","volume":"8","author":"RF Sowade","year":"2017","unstructured":"Sowade RF, Jahn TR. Seed-induced acceleration of amyloid-\u03b2 mediated neurotoxicity in vivo. Nat Commun. 2017;8(1):512.","journal-title":"Nat Commun"},{"issue":"374","key":"383_CR66","doi-asserted-by":"publisher","first-page":"eaag0481","DOI":"10.1126\/scitranslmed.aag0481","volume":"9","author":"SL DeVos","year":"2017","unstructured":"DeVos SL, Miller RL, Schoch KM, Holmes BB, Kebodeaux CS, Wegener AJ, et al. Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy. Sci Transl Med. 2017;9(374):eaag0481.","journal-title":"Sci Transl Med."},{"issue":"43","key":"383_CR67","doi-asserted-by":"publisher","first-page":"11524","DOI":"10.1073\/pnas.1710311114","volume":"114","author":"CEG Leyns","year":"2017","unstructured":"Leyns CEG, Ulrich JD, Finn MB, Stewart FR, Koscal LJ, Remolina Serrano J, et al. TREM2 deficiency attenuates neuroinflammation and protects against neurodegeneration in a mouse model of tauopathy. Proc Natl Acad Sci U S A. 2017;114(43):11524\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"19","key":"383_CR68","doi-asserted-by":"publisher","first-page":"4335","DOI":"10.1523\/JNEUROSCI.2590-20.2021","volume":"41","author":"DH Oakley","year":"2021","unstructured":"Oakley DH, Klickstein N, Commins C, Chung M, Dujardin S, Bennett RE, et al. Continuous monitoring of tau-induced neurotoxicity in patient-derived iPSC-neurons. J Neurosci. 2021;41(19):4335.","journal-title":"J Neurosci"},{"issue":"2","key":"383_CR69","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41583-018-0113-1","volume":"20","author":"CM Henstridge","year":"2019","unstructured":"Henstridge CM, Hyman BT, Spires-Jones TL. Beyond the neuron-cellular interactions early in Alzheimer disease pathogenesis. Nat Rev Neurosci. 2019;20(2):94\u2013108.","journal-title":"Nat Rev Neurosci"},{"issue":"11","key":"383_CR70","doi-asserted-by":"publisher","first-page":"3853","DOI":"10.1096\/fj.201600756R","volume":"30","author":"EJ Goetzl","year":"2016","unstructured":"Goetzl EJ, Mustapic M, Kapogiannis D, Eitan E, Lobach IV, Goetzl L, et al. Cargo proteins of plasma astrocyte-derived exosomes in Alzheimer\u2019s disease. FASEB J. 2016;30(11):3853\u20139.","journal-title":"FASEB J"},{"issue":"3","key":"383_CR71","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/j.ajpath.2011.05.047","volume":"179","author":"A Serrano-Pozo","year":"2011","unstructured":"Serrano-Pozo A, Mielke ML, G\u00f3mez-Isla T, Betensky RA, Growdon JH, Frosch MP, et al. Reactive glia not only associates with plaques but also parallels tangles in Alzheimer\u2019s disease. Am J Pathol. 2011;179(3):1373\u201384.","journal-title":"Am J Pathol"},{"issue":"47","key":"383_CR72","doi-asserted-by":"publisher","first-page":"9262","DOI":"10.1523\/JNEUROSCI.0146-18.2019","volume":"39","author":"CD Fowler","year":"2019","unstructured":"Fowler CD. NeuroEVs: characterizing extracellular vesicles generated in the neural domain. J Neurosci. 2019;39(47):9262\u20138.","journal-title":"J Neurosci"},{"issue":"3","key":"383_CR73","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.1002\/jex2.35","volume":"1","author":"DE Gomes","year":"2022","unstructured":"Gomes DE, Witwer KW. L1CAM-associated extracellular vesicles: A systematic review of nomenclature, sources, separation, and characterization. J Extracell Biol. 2022;1(3):e35.","journal-title":"J Extracell Biol."},{"issue":"47","key":"383_CR74","doi-asserted-by":"publisher","first-page":"9269","DOI":"10.1523\/JNEUROSCI.0147-18.2019","volume":"39","author":"AF Hill","year":"2019","unstructured":"Hill AF. Extracellular vesicles and neurodegenerative diseases. J Neurosci. 2019;39(47):9269\u201373.","journal-title":"J Neurosci"},{"issue":"6","key":"383_CR75","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/s41592-021-01174-8","volume":"18","author":"M Norman","year":"2021","unstructured":"Norman M, Ter-Ovanesyan D, Trieu W, Lazarovits R, Kowal EJK, Lee JH, et al. L1CAM is not associated with extracellular vesicles in human cerebrospinal fluid or plasma. Nat Methods. 2021;18(6):631\u20134.","journal-title":"Nat Methods"},{"issue":"1","key":"383_CR76","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1093\/brain\/awac258","volume":"146","author":"J Blommer","year":"2023","unstructured":"Blommer J, Pitcher T, Mustapic M, Eren E, Yao PJ, Vreones MP, et al. Extracellular vesicle biomarkers for cognitive impairment in Parkinson\u2019s disease. Brain. 2023;146(1):195\u2013208.","journal-title":"Brain"},{"issue":"20","key":"383_CR77","doi-asserted-by":"publisher","first-page":"13647","DOI":"10.1021\/acs.analchem.0c03092","volume":"92","author":"Y Fu","year":"2020","unstructured":"Fu Y, Jiang C, Tofaris GK, Davis JJ. Facile impedimetric analysis of neuronal exosome markers in Parkinson\u2019s disease diagnostics. Anal Chem. 2020;92(20):13647\u201351.","journal-title":"Anal Chem"},{"issue":"7","key":"383_CR78","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1136\/jnnp-2019-322588","volume":"91","author":"C Jiang","year":"2020","unstructured":"Jiang C, Hopfner F, Katsikoudi A, Hein R, Catli C, Evetts S, et al. Serum neuronal exosomes predict and differentiate Parkinson\u2019s disease from atypical parkinsonism. J Neurol Neurosurg Psychiatry. 2020;91(7):720\u20139.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"383_CR79","doi-asserted-by":"publisher","first-page":"278","DOI":"10.3389\/fnins.2017.00278","volume":"11","author":"M Mustapic","year":"2017","unstructured":"Mustapic M, Eitan E, Werner JK Jr, Berkowitz ST, Lazaropoulos MP, Tran J, et al. Plasma extracellular vesicles enriched for neuronal origin: a potential window into brain pathologic processes. Front Neurosci. 2017;11:278.","journal-title":"Front Neurosci"},{"issue":"6","key":"383_CR80","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1111\/ene.14208","volume":"27","author":"M Niu","year":"2020","unstructured":"Niu M, Li Y, Li G, Zhou L, Luo N, Yao M, et al. A longitudinal study on alpha-synuclein in plasma neuronal exosomes as a biomarker for Parkinson\u2019s disease development and progression. Eur J Neurol. 2020;27(6):967\u201374.","journal-title":"Eur J Neurol"},{"issue":"7","key":"383_CR81","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.3390\/cells9071618","volume":"9","author":"CJ Nogueras-Ortiz","year":"2020","unstructured":"Nogueras-Ortiz CJ, Mahairaki V, Delgado-Peraza F, Das D, Avgerinos K, Eren E, et al. Astrocyte- and neuron-derived extracellular vesicles from Alzheimer\u2019s disease patients effect complement-mediated neurotoxicity. Cells. 2020;9(7):1618.","journal-title":"Cells"},{"issue":"6","key":"383_CR82","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1007\/s13365-020-00877-6","volume":"26","author":"L Pulliam","year":"2020","unstructured":"Pulliam L, Liston M, Sun B, Narvid J. Using neuronal extracellular vesicles and machine learning to predict cognitive deficits in HIV. J Neurovirol. 2020;26(6):880\u20137.","journal-title":"J Neurovirol"},{"issue":"5","key":"383_CR83","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1007\/s13365-018-0695-4","volume":"25","author":"L Pulliam","year":"2019","unstructured":"Pulliam L, Sun B, Mustapic M, Chawla S, Kapogiannis D. Plasma neuronal exosomes serve as biomarkers of cognitive impairment in HIV infection and Alzheimer\u2019s disease. J Neurovirol. 2019;25(5):702\u20139.","journal-title":"J Neurovirol"},{"issue":"1","key":"383_CR84","doi-asserted-by":"publisher","first-page":"e13754","DOI":"10.1111\/acel.13754","volume":"22","author":"M Vreones","year":"2023","unstructured":"Vreones M, Mustapic M, Moaddel R, Pucha KA, Lovett J, Seals DR, et al. Oral nicotinamide riboside raises NAD+ and lowers biomarkers of neurodegenerative pathology in plasma extracellular vesicles enriched for neuronal origin. Aging Cell. 2023;22(1):e13754.","journal-title":"Aging Cell"},{"issue":"1","key":"383_CR85","doi-asserted-by":"publisher","first-page":"1348885","DOI":"10.1080\/20013078.2017.1348885","volume":"6","author":"LJ Vella","year":"2017","unstructured":"Vella LJ, Scicluna BJ, Cheng L, Bawden EG, Masters CL, Ang CS, et al. A rigorous method to enrich for exosomes from brain tissue. J Extracell Vesicles. 2017;6(1):1348885.","journal-title":"J Extracell Vesicles"},{"issue":"1","key":"383_CR86","doi-asserted-by":"publisher","first-page":"e12183","DOI":"10.1002\/jev2.12183","volume":"11","author":"Y You","year":"2022","unstructured":"You Y, Muraoka S, Jedrychowski MP, Hu J, McQuade AK, Young-Pearse T, et al. Human neural cell type-specific extracellular vesicle proteome defines disease-related molecules associated with activated astrocytes in Alzheimer\u2019s disease brain. J Extracell Vesicles. 2022;11(1):e12183.","journal-title":"J Extracell Vesicles"},{"issue":"6","key":"383_CR87","doi-asserted-by":"publisher","first-page":"2951","DOI":"10.3390\/ijms22062951","volume":"22","author":"F Anastasi","year":"2021","unstructured":"Anastasi F, Masciandaro SM, Carratore RD, Dell\u2019Anno MT, Signore G, Falleni A, et al. Proteomics profiling of neuron-derived small extracellular vesicles from human plasma: enabling single-subject analysis. Int J Mol Sci. 2021;22(6):2951.","journal-title":"Int J Mol Sci."}],"container-title":["Translational Neurodegeneration"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40035-023-00383-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40035-023-00383-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40035-023-00383-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T21:03:05Z","timestamp":1701810185000},"score":1,"resource":{"primary":{"URL":"https:\/\/translationalneurodegeneration.biomedcentral.com\/articles\/10.1186\/s40035-023-00383-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,4]]},"references-count":87,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["383"],"URL":"https:\/\/doi.org\/10.1186\/s40035-023-00383-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3131295\/v1","asserted-by":"object"}]},"ISSN":["2047-9158"],"issn-type":[{"value":"2047-9158","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,4]]},"assertion":[{"value":"10 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal care and experimental procedures complied with the National Institutes of Health guidelines on animal care and were reviewed for ethical use of animals and approved by the Johns Hopkins University Animal Care and Use Committee (protocol #MO20M71; approved on 18 March 2020).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"CT, AGT, RR, NJH and BSS are listed as inventors in patent applications filed by Johns Hopkins Technology Ventures covering novel compositions and utilities of nSMase2 inhibitors, including PDDC. This arrangement has been reviewed and approved by the Johns Hopkins University in accordance with its conflict-of-interest policies. Other authors declare that no conflict of interest exist.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"56"}}